Statin initiation after myocardial infarction in patients with alcohol‐related liver disease: A nationwide population‐based study
Liver International · 2024
DOI: 10.1111/liv.15912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Axel Wester und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Myocardial Infarction, Liver Diseases, Alcoholic. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mag-TarmFonden, Swedish Gastroenterology Society, Bengt Ihres Foundation, Stiftelsen Professor Nanna Svartz Fond.
Abstract (Originalsprache)
Background and Aims Secondary prevention with statins improves clinical outcomes after myocardial infarction (MI). We aimed to compare odds of statin initiation after MI in patients with co‐existing alcohol‐related liver disease (ALD) to the general population, and the association between statin initiation and mortality in the patients with ALD.
Methods
All statin‐naïve patients with ALD and a first‐time MI between 2006 and 2020 were identified from Swedish healthcare registers and matched for age, sex, and year of MI with up to ten ALD‐free general population controls with a first‐time MI. Logistic regression was used to estimate adjusted odds ratios (OR) for statin initiation within 30 days after MI for ALD patients versus controls. Cox regression was used in patients with ALD to compare mortality between statin initiators and non‐initiators.
Results
Of the 276 patients with a first‐time MI and ALD, 206 (74.6%) were male, the median age was 67 (interquartile range 62–72), 151 (54.7%) had cirrhosis, and 62 (22.5%) had decompensated cirrhosis. 1769 matched controls were included. Initiation of statins was less common in ALD patients (50.0%) than controls (89.2%, adjusted OR = .15, 95% confidence interval [CI] = .10–.20). Among patients with ALD, statin initiators and non‐initiators were followed for a median of 3.9 (interquartile range = 1.8–7.7) and 1.9 years (interquartile range = .5–4.4), respectively. Statin initiators had lower mortality than non‐initiators (adjusted hazard ratio = .41, 95%CI = .28–.59).
Conclusions
Patients with ALD less often initiated statins after MI than the general population. Statin initiation was associated with improved survival, suggesting that patients with ALD might be undertreated following MI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
- Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Axel Wester, Peter Jepsen, Hannes Hagström
Förderung
- Mag-TarmFonden, Swedish Gastroenterology Society
- Bengt Ihres Foundation
- Stiftelsen Professor Nanna Svartz Fond
- Stockholm läns landsting
- Novo Nordisk Fonden
- Vetenskapsrådet
- Cancerfonden
- Stiftelsen Syskonen Svenssons Stiftelse för Medicinsk Forskning
Zitieren
APA
Wester, A., Jepsen, P., & Hagström, H. (2024). Statin initiation after myocardial infarction in patients with alcohol‐related liver disease: A nationwide population‐based study. Liver International. https://doi.org/10.1111/liv.15912
Vancouver
Wester A, Jepsen P, Hagström H. Statin initiation after myocardial infarction in patients with alcohol‐related liver disease: A nationwide population‐based study. Liver International. 2024. doi:10.1111/liv.15912
BibTeX
@article{Wester2024,
author = {Wester, Axel and Jepsen, Peter and Hagström, Hannes},
title = {Statin initiation after myocardial infarction in patients with alcohol‐related liver disease: A nationwide population‐based study},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15912}
}
EUVIMED